Report of the American Diabetes Asociation's task force on standardization of the insulin assay

Diabetes

Volumn 45, Issue 2, 1996, Pages 242-256

  Robbins, David C ^l   Andersen, Lennart ^a   Bowsher, Ron ^c   Chance, Ron ^c   Dinesen, Bo ^b   Frank, Bruce ^c   Gingerich, Ron ^e   Goldstein, David ^d   Widemeyer, Hsaio Mei ^d   Haffner, Steven ^f   Hales, C Nick ^g   Jarett, Leonard ^h   Polonsky, Kenneth ⁱ   Porte, Daniel ^j   Skyler, Jay ^k   Webb, George ^l   Gallagher, Kathy ^l  

^a NOVO NORDISK A S   (Denmark)

^b STENO DIABETES CENTER   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

^d University of Missouri   (United States)

^e Linco Research   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l Medlantic Research Institute   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PROINSULIN;

ACCURACY; ARTICLE; BIOASSAY; BLOOD LEVEL; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE DETERMINATION; HUMAN; HUMAN TISSUE; LABORATORY TEST; MEDICAL SOCIETY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STANDARDIZATION;

DIABETES MELLITUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN; RADIOIMMUNOASSAY; SOCIETIES, SCIENTIFIC;

EID: 0030027254     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diab.45.2.242     Document Type: Article

References (25)

1. Yalow RS, Berson SA: Immunoassay of endogenous plasma insulin in man J Clin Invest 39 1157-1175, 1960
2. Cotes PM, Mussett MV, Berryman I, Ekins R, Glover S, Hales N, Hunter WM, Lowy C, Neville RWJ, Samols E, Woodward PM: Collaborative study of estimates by radioimmunoassay of insulin concentrations in plasma samples examined in groups of five or six laboratories. J Endocrinol 45.557-569, 1969
3. Marschner I, Bottermann P, Erhardt F, Linke R, Lffler G, Maier V, Schwandt P: Group experiments on the radioimmunological insulin determination. Horm Metab Res 6:293-296, 1974
4. Shishiba Y, Irie M, Yamada H, Kinoshita F: An inter- and intralaboratory quality-control survey of radioimmunoassay of insulin, thyroxin, thyrotropin, cortisol, digoxin, gastrin, ′2-microglobulin, and IgE in Japan with commercially available kits. Clin Chem 29:1501-1507, 1983
5. Birstow, AF, Gaines Das RE, Bangham DR: World Health Organization standards for highly purified human, porcine and bovine insulins. J Biol Stand 16.163-178, 1988
6. Vølund A, Brange J, Drejer K, Jensen I, Markussen J, Ribel U, Søvensen AR, Schlichtkrull J: In vitro and in vivo potency of insulin analogues designed for clinical use. Diabetic Med 8:839-847, 1991
7. Vølund A: Conversion of insulin units to SI units. Am J Clin Nutr 58.714-715, 1993
8. Sicree RA, Zimmett PZ, King HOM, Coventry JS: Plasma insulin response among Nauruans prediction of deterioration in glucose tolerance over 6 yrs. Diabetes 36:179-186, 1987
9. Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK: Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity and body fat distribution. Diabetes 39:283-288, 1990
10. Bergstrom RW, Newell-Morris LL, Leonetti DL, Shuman WP, Wahl PW, Fujimoto WY: Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese American men. Diabetes 39:104-111, 1990
11. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR Relationship of proinsulin and insulin to cardiovascular risk factors in non-diabetic subjects. Diabetes 42:1297-1302, 1993
12. Vardi P, Crisa L, Jackson RA: Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34:93-102, 1991
13. Ward WK, LaCova EC, Paquette TL, Beard JC, Wallom BJ, Porte D: Disproportionate elevation of immunoreactive proinsulin in type II (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 30:698-702, 1987
14. Saad MF, Kahn SE, Nelson RG, Pettitt DJ, Knowler WC, Schwartz MW, Kowalyk S, Bennett PH, Porte D Jr: Disproportionately elevated proinsulin in Pima Indians with non-insulin dependent diabetes mellitus J Clin Endocrinol Metab 70:1247-1253, 1990
15. Temple RC, Carrington CA, Luzio SD, Owens DR, Schneider AE, Sobey WJ, Hales CN Insulin deficiency in non-insulin dependent diabetes. Lancet i:293-295, 1989
16. Davies M, Rayman G, Gray IP, Day JL, Hales CN: Insulin deficiency and increased plasma concentrations of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance. Diabetic Med 10:313-320, 1993
17. Mykkänen L, Kuusisto J, Hales CN, Pyörälä K, Laakso M, Haffner, SM: Serum proinsulin levels are disproportionately increased in elderly prediabetic subjects (Abstract). Diabetologia 37 (Suppl. 1):A74, 1994
18. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY: Proinsulin as a marker for development of NIDDM in Japanese-American men. Diabetes 44:173-179, 1995
19. Reaven GM: 1988 Banting Lecture: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
20. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP: Prospective analyses of the insulin resistance syndrome (syndrome X). Diabetes 41:715-722, 1992
21. Nagi DK, Hendra TJ, Ryle AJ, Cooper TM, Temple RC, Clark PM, Schneider AE, Hales CN, Yudkin JS: The relationship of concentrations of insulin, intact proinsulin, and 32-33 split proinsulin with cardiovascular risk factors in type II (non-insulin-dependent) diabetic subjects. Diabetologia 33:532-537, 1990
22. Haffner SM, Mykkänen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR: Relationship of proinsulin and insulin to cardiovascular risk factors in non-diabetic subjects. Diabetes 42:1297-1302, 1993
23. Buick AR, Doig MV, Jeal SC, Land GS, McDowall RD: Method validation in the bioanalytical laboratory. J Pharm & Biomed Anal 8:629-637, 1990
24. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacob A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S: Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81:309-312, 1992
25. Armbruster DA, Tillman MD, Hubbs LM: Limit of detection (LOD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 40:1233-1238, 1994